Correlation between the suppressor of cytokine signaling-1 and 3 and hepatitis B virus: possible roles in the resistance to interferon treatment by Ling-yao Du et al.
Du et al. Virology Journal 2014, 11:51
http://www.virologyj.com/content/11/1/51RESEARCH Open AccessCorrelation between the suppressor of cytokine
signaling-1 and 3 and hepatitis B virus: possible
roles in the resistance to interferon treatment
Ling-yao Du1,2, Yao-li Cui1,2, En-qiang Chen1,2, Xing Cheng1,2, Li Liu1,2 and Hong Tang1,2*Abstract
Background: The suppressor of cytokine signaling family (SOCS) is an important negative regulator in the JAK-STAT
signaling pathway. This study was designed to explore the correlation between SOCS-1, 2 and 3, Hepatitis B Virus
(HBV) and interferon (IFN), and the relationship between SOCS and IFN therapeutic efficacy.
Methods: Four types of mouse models were established. Mice were administered with HBV replicative plasmid
pHBV4.1 and IFN inducer Poly IC (Group A), pHBV4.1 (Group B), Poly IC (Group C) and saline (Group D), respectively.
Liver tissues were harvested from the mice and SOCS expression was determined. Meanwhile, patients with chronic
hepatitis B (CHB) were treated with pegylated interferon α-2b for 24-48 weeks. Liver biopsy was collected and
the baseline SOCS expression was determined. Serum assay was performed for efficacy evaluation and correlation
analysis.
Results: In animal studies, the expression level of SOCS-1 and 3 was found in the descending order of B, A, C and D.
The difference between Group B and D suggested that HBV could induce SOCS. The difference between Group A and
C suggested that HBV could still induce SOCS with up-regulated endogenous IFN. The difference between Group C
and D suggested that ploy IC could induce SOCS, while the difference between Group B and A suggested that Poly IC
might have a stronger inhibition effect for SOCS. There was no difference in SOCS-2 expression. In clinical studies, eight
of twenty-four enrolled patients achieved either complete or partial therapeutic response. The expression of both
SOCS-1 and 3 was higher in CHB patients than in normal controls. The baseline HBV-DNA level was positively correlated
with SOCS-1 and 3. The age, viral genotype, HBVDNA, SOCS-1 and SOCS-3 were found to be related to IFN efficacy.
Conclusion: HBV could induce both SOCS-1 and 3 expression regardless of endogenous IFN level. Elevated IFN could
directly up-regulate SOCS-1 and 3 expression, but it could also indirectly down-regulate SOCS-1 and 3 expression by
inhibiting HBV replication. HBV might play a more important role in the SOCS up-regulation than IFN, a possible reason
why patients with high HBV viral load encounter poor efficacy of IFN treatment.
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The antiviral therapy, immunomodulatory therapy and
anti-inflammatory therapy are the most common treat-
ments for patients with Chronic Hepatitis B (CHB) [1],
among which the antiviral therapy with interferon (IFN)
or nucleoside analogues (NA) is the key treatment [2,3].
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reproduction in any medium, provided the oras an antiviral drug. However, there are still many un-
known impact factors that affect its efficacy [4,5]. The
therapeutic efficacy of INF is mainly achieved through
the complicated “IFN System” where several signaling
transduction pathways are activated by the binding of
INF-α to INF-α receptor (INFAR). The pathway of Janus
kinase-the signal transducer and activator of transcrip-
tion (JAK-STAT) is one of the typical pathways [6]. In
this pathway, INF-α binds to INFAR-I on the membrane
to form a dimer, which activates Jak-1 and Tyk2, the sig-
nal transducers in the cytoplasm, to phosphorylate andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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translocates into the nucleus to bind the interferon-
sensitive response elements (IFNSRE). Antiviral protein
products are then induced to inhibit HBV-DNA tran-
scription, promote HBV mRNA degradation and sup-
press HBV protein translation [7,8].
The suppressor of cytokine signaling (SOCS) is in-
duced by cytokines and is an important negative regula-
tory factor in the JAK-STAT signaling pathway. So far,
eight members of the SOCS family have been found,
which include SOCS 1-7 and cytokine inducible Src
Homology 2 (SH2) containing protein (CIS). They all
consist of an amino-terminus, a SH2 domain in the mid-
dle, and a SOCS box in carboxy-terminus [9-11]. It has
been demonstrated that SOCS protein could inhibit the
activity of JAKs and compete with STAT2 to bind to
the phosphorylated tyrosine residues in cytokine re-
ceptors through its SH2 domain. As a result, the phos-
phorylation of STATs is reduced. SOCS protein could
also mediate the degradation pathways of the activated
signaling proteins or bind to the cytoplasmic protein
tyrosine phosphatase SHP2, thus inhibiting the signal
transduction [12].
Recent studies have suggested that SOCS-1 and SOCS-3
are the negative regulators in the IFN signal transduction
pathway in patients with chronic hepatitis C (HCV) infec-
tion. HCV core protein can induce SOCS-3 protein expres-
sion to reduce the therapeutic effect of IFN-α [13-15].
However, in CHB patients with IFN treatment, it’s unclear
whether SOCS related elements impact INF efficacy in
addition to HBV genotype and viral load. Therefore, fur-
ther investigation is required to determine the correlation
between SOCS expression, HBV and IFN therapeutic effi-
cacy in CHB patients. In this study, mouse models of HBV
replication were established to explore the interactions be-
tween SOCS expression and HBV. The expression of
SOCS family in CHB patients during IFN treatment was
also investigated to explore the correlation between the




Twenty-four healthy BALB/c male mice at 6-9 weeks of
age and 18-20 g of weight were purchased from Experi-
mental Animal Center, Sichuan University, and divided
into four groups. Mice in Group A were administered
with the replicative HBV plasmid DNA pHBV4.1-DNA
(10 μg pHBV4.1-DNA dissolved in saline equivalent to
8% mouse body weight) via the caudal vein using high-
pressure injection. 24 hours after the injection, the mice
were injected intraperitoneally with Poly IC at 200 μL/day
from day 0 to day 3. Mice in Group B were administered
with an equal dose of pHBV4.1-DNA via the caudal veinas in Group A, followed by intraperitoneal injection of sa-
line at 200 μL/day from day 0 to day 3. Mice in Group C
received the caudal vein high-pressure injection of an
equal volume of saline and the intraperitoneal injection of
Poly IC at 200 μL/day. Mice in Group D received both the
caudal vein high-pressure and intraperitoneal injection of
saline. Six hours after the last injection, these mice were
euthanized and the liver tissues were harvested.
The plasmid DNA pHBV4.1-DNA we used here is an
HBV replication competent plasmid. It contains 1.3 cop-
ies of the HBV genome of serotype ayw and is capable of
HBV transcription, replication and expression both in vitro
and vivo [16,17]. It’s kindly given by the Scripps Research
Institute, La Jolla, CA, USA as a gift. The mouse model we
established here was verified effective in our previous stud-
ies. It’s a transient HBV transfection model with viral repli-
cation and expression lasting for 10 days and peaking at
day 3 and day 4. It fulfilled the applicable requirement in
the study of HBV and related host factors [18].
Tissue sample analysis
Part of the mouse liver was fixed by formalin for immu-
nohistochemical staining to detect the expression of
SOCS proteins. Primary antibodies included anti-SOCS-
1, anti-SOCS-2 (Santa Cruz) and anti-SOCS-3 (Abcam).
PBS was used as the negative control for primary anti-
bodies. Samples with known SOCS expression were used
as the positive controls. As the SOCS proteins would be
stained brown, positive sample was defined as those with
stained particles present in the cytoplasm, or with
stained cytoplasm. Two pathologists with no prior
knowledge of the study were asked to score the tissue
sections according the Axiotis score standard. The per-
centage of positive cells and intensity of positive staining
scored as follows:
Percentage score
0 = 0 ~ 10% positive cells;
1 = 11 ~ 25% positive cells;
2 = 26 ~ 50% positive cells;
3 = 51 ~ 75% positive cells;
4 = 76 ~ 100% positive cells.
Intensity score




The sum of the percentage score and intensity score
equaled the final score if there was no difference in two
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would equal the final score [19].
The remaining liver tissue was put in liquid nitrogen
immediately after the harvest and stored at -70°C. Tis-
sues were ground into powder in liquid nitrogen. Total
RNAs were extracted from the ground liver tissue and re-
versely transcribed into total cDNA by RT-PCR amplifica-
tion. The sequences of mouse SOCS-1, SOCS-2, SOCS-3
and GAPDH genes were amplified from cDNA forFigure 1 The expression of SOCS-1 in mouse liver tissues. A. Represen
tissues (×400. HE) and statistical diagram of score; B. Representative RT-P
of three times results quantified and expressed as a ratio of SOCS-1/GAPDH; C.
mouse liver tissues and statistical diagram of three times results quantified andsemiquantitative analysis. Protein samples extracted
from liver powder were analyzed using western blot-
ting to evaluate the expression of SOCS proteins.
Clinical studies
Study design
All human subjects enrolled should meet the criteria in-
cluding qualified age from eighteen to sixty-five years
old, free of antiviral and immunomodulating treatmenttative IHC images showing the expression of SOCS-1 in mouse liver
CR image of SOCS-1 mRNA in mouse liver tissues and statistical diagram
Representative western blotting image of SOCS-1 proteins expression in
expressed as the ratio of SOCS-1/GAPDH.
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in the past 24 hours and effective contraception in both
sexes during the study. They should also have positive
serum HBsAg for more than 24 weeks, elevated serum
HBV-DNA at more than 5 × 105copies/ml and twice ele-
vated ALT between 2-10 ULN in the past 6 months. All
subjects were provided with written informed consent.
The exclusion criteria included lactating women, de-
creased albumin at less than 3.5 g/L, extended prothrom-
bin time for more than 4 s, elevated serum bilirubin at
more than 34umol/L, decreased neutrophile granulocytes
at less than 1.5 × 109/L, decreased platelets at less than
9.0 × 1012/L, coinfection with other hepatitis viruses and
accompaniment of diabetes, thyroid dysfunction, auto-
immune diseases and psychological issues.
After the enrollment, all human subjects were sub-
cutaneously administered with pegylated interferon α-2b
(Peg-Intron™, Schering Plough, USA), with the dosage
and duration varied based on the individual weight, and
both personal choice and therapeutic response, respect-
ively. The observation lasted for 48 weeks and had little
impact on the conventional medical course. All subjects
accepted physical examination, serum assay and liver bi-
opsy before the treatment. At Week 12, 24 and 48 dur-
ing the treatment only physical examination and serum
assay were performed for therapeutic response evaluation.
Sample analysis
The liver tissue from the human subjects was examined
by immunohistochemistry to evaluate the expression of
SOCS family. Normal liver tissue sample was obtained
from the tissue bank of West China Hospital, SCU. As
mentioned before, the SOCS proteins would be stained
brown as well. Samples with stained particles in theFigure 2 The expression of SOCS-2 in mouse liver tissues. A. Represen
statistical diagram of three times results quantified and expressed as a rati
proteins expression in mouse liver tissues and statistical diagram of three timecytoplasm were defined as positive samples. The expres-
sion level of SOCS were also scored by the two patholo-
gists mentioned before.
The serum samples collected at each medical assess-
ment were detected for HBV-DNA quantification (Light-
cycler-480, Roche, Switzerland), serum makers of HBV
infection (Alisei Quality System, RADIM, Italy), liver
and kidney function (Modular EVO, Roche, Switzerland)
and prothrombin time (Sysmex CA-7000 Systems, Sys-
mex, Japan). The human subjects also received routine
blood and urine examination and electrocardiogram. Ac-
cording to the therapeutic efficacy, those with complete
or partial virological, serological or biochemical re-
sponses were assigned into the response group, while
the rest were assigned into the non-response group.
Statistical analysis
Five different areas of each liver tissue section after im-
munohistochemical staining were scored and the RT-
PCR and western blotting were repeated three times.
The result of RT-PCR amplification was semi-quantified
by a professional image analysis software Image Pro Plus
4.5 (Media Cybernetics Inc, Silver Spring, MD,USA).
The outcome of western blotting was semi-quantified by
Image J, a public domain Java image processing program
inspired by NIH Image for the Macintosh. All data were
used for statistical analysis. Measurement data were
tested for normality and presented as mean ± standard
deviation. Statistical analysis was performed by t test, χ2
test, and Wilcoxon and Spearman’s rank correlation test
for measurement data, enumeration data, and ranked
data, respectively. Logistic regression was used to deter-
mine the factors that would affect the efficacy of PEG-
IFN treatment in the CHB patients. All statistical analysistative RT-PCR image of SOCS-2 mRNA in mouse liver tissues and
o of SOCS-2/GAPDH; B. Representative western blotting image of SOCS-2
s results quantified and expressed as the ratio of SOCS-2/GAPDH.
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Ethics statement
This study was approved by both the Laboratory Animal
ethics committee of Sichuan University and the West
China Hospital Ethics Committee. Written informed con-
sents were obtained from all patients before we carried
out the liver biopsy.Figure 3 The expression of SOCS-3 in mouse liver tissues. A. Represen
(×400. HE) and statistical diagram of score; B. Representative RT-PCR image of S
results quantified and expressed as a ratio of SOCS-3/GAPDH; C. Representative
tissues and statistical diagram of three times results quantified and exprResults
Animal studies
Expression of SOCS-1 in liver tissues
In this study, four groups of mice were administered
with HBV replicative plasmid pHBV4.1 followed with
IFN inducer Poly IC (Group A), pHBV4.1 (Group B),
Poly IC (Group C) and saline (Group D), respectively.
SOCS-1 expression was found in all four groups with
the SOCS-1 expression level in descending order fromtative IHC images showing the expression of SOCS-3 in mouse liver tissues
OCS-3 mRNA in mouse liver tissues and statistical diagram of three times
western blotting image of SOCS-3 proteins expression in mouse liver
essed as the ratio of SOCS-3/GAPDH.
Table 1 General information of the enrolled 24 CHB
patients
Patients (n = 24)
Age (years) (Mean ± SD) 25.54 ± 8.08
Gender (Male/Female) 17 / 7
Gene Type (A/B/C) 1 / 14 / 9
HBeAg (+/–) 24 / 0
HBeAb (+/–) 0 / 24
ALT (IU/L) 224.79 ± 95.82
AST (IU/L) 107.00 ± 62.45
ALB (g/L) 36.98 ± 2.21
TBIL (mg/dL) 18.50 ± 11.57
CHE (U/L) 5857.50 ± 623.08
INR for PT 2.26 ± 0.57
HBV DNA level (lg IU/ml) 17.17 ± 1.84
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try, RT-PCR, and western blotting (Figure 1). The ex-
pression of SOCS-1 in Group B was significantly higher
than that in Group D, suggesting that HBV could induce
the expression of SOCS-1. The expression difference be-
tween Group A and C suggested that HBV could still in-
duce SOCS with up-regulated endogenous IFN. The
expression in Group C was significantly higher than that
in Group D, suggesting that after the direct up-regulation
of endogenous IFN, SOCS-1 expression might be up-
regulated via some negative feedback pathway. The ex-
pression in Group B was significantly higher than that in
Group A, suggesting that Poly IC might not only mediate
the up-regulation of SOCS-1 via increasing endogenous
IFN level to inhibit HBV replication, but also have a stron-
ger inhibiting effect than its inducing ability.
Expression of SOCS-2 in liver tissues
There was no significant difference in SOCS-2 expres-
sion levels in all groups as determined by RT-PCR and
western blotting (Figure 2), suggesting that the expres-
sion of SOSC-2 in mouse liver was affected by neither
HBV nor Poly IC.
Expression of SOCS-3 in liver tissues
Consistent with the expression of SOCS-1, SOCS-3
positive cells were found in all groups using immunohis-
tochemistry. The expression level of SOCS-3 was in the
descending order of B > A > C > D (Figure 3), same asTable 2 The therapeutic response in CHB patients after treatm
Treatment
course
Responders (N = 8)
HBeAg seroconversion Non-HBeAg seroconvers
24 weeks 3 2
48 weeks 3 0that of SOCS-1. These results suggested that the expres-
sion of SOCS-3 and SOCS-1 was similarly mediated by
HBV and Poly IC.
Clinical studies
Subjects
Twenty-four subjects, including 17 female and 7 male,
were enrolled for clinical observation. The average age
was 25.54 years old. Detailed patient information was
listed (Table 1).
Therapeutic response to PEGINF α-2b in CHB patients
Fourteen patients (14/24) received 24 weeks’ treatment,
and among them 5 achieved either complete or partial
therapeutic response according to the judgmental cri-
teria of the therapeutic responses in subjects. Among
these 5 patients, 3 achieved HBeAg seroconversion. An-
other ten patients (10/24) received 48 weeks’ treatment,
and among them 3 achieved HBeAg seroconversion. The
8 patients who achieved either complete or partial thera-
peutic response were assigned into the responder group,
while the remaining 16 patients were assigned into the
non-responder group (Table 2).
Expression of SOCS-1, 2 and 3 in the liver tissue of normal
controls and CHB patients before treatment
Both SOCS-1-positive and SOCS-3 positive cells were
observed in the liver tissues of the CHB patients from
both the responder and non-responder groups. SOCS-1
and SOCS-3 were mainly found in the cytoplasm of the
hepatocytes. In contrast, only a trace of SCOS-3 was
found in the liver tissues from the normal controls
(Figure 4). In addition, there was a significant differ-
ence in the expression level of both SOCS-1 and
SOCS-3 between the responder and non-responder
groups before the treatment. The expression of SOCS-
1 and SOCS-3 was higher in the non-responder group
than in the responder group. SOCS-2 was not detected
in any of the liver tissues examined.
Factors affecting the therapeutic efficacy
Four serum assays representing the hepatic function
were performed before the treatment. Results were ana-
lyzed for correlation with SOCS-1 and SOCS-3 using
Spearman Rank Correlation Test. Only the baseline
HBV-DNA level was positively correlated with SOCS-1
and SOCS-3 (p < 0.05), while none of the ALT, AST orent.
Non-responders (N = 16)
ion HBeAg seroconversion Non-HBeAg seroconversion
0 9
0 7
Figure 4 The expression of SOCS-1, 2 and 3 proteins in patients before treatment. The representative IHC images showing expression of
SOCS-1, SOCS-2 and SOCS-3 proteins in all CHB patients before treatment and normal controls as well as the statistical diagram of score.
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or SOCS-3 (Table 3).
To investigate the factors which might affect the thera-
peutic efficacy of PEGINF α-2b, 15 possible factors in-
cluding SOCS-1 and SOCS-3 expression level were
chosen for the univariate analysis. Five factors showed
significant differences between the responder and non-
responder groups, suggesting that SOCS-1 and SOCS-3,
in addition to the gender, viral genotype and HBV-DNA,
might impact the therapeutic response (Table 4).
Logistic regression was used to determine the correl-
ation between the 15 factors. Five variables including
gender, viral genotype, HBV-DNA, SOCS-1 and SOCS-3
were admitted into the regression model (Table 5). To
prove the sensitivity and specificity of the model, the re-
ceiver operating characteristic curve (ROC curve) and
cut-off point were calculated. The area under the ROC
curve in this logistic regression model was 82.68% and
the cut-off point was 0.50, suggesting that the model
was valid.
Discussion
CHB patients usually encounter poor therapeutic response
with IFN treatment. Therefore, we set to determineTable 3 The correlation between SOCS family, liver function a
S
Item Mean ± SD Correlation
ALT (IU/L) 224.79 ± 95.82 −0.29
AST (IU/L) 107.00 ± 62.45 −0.17
TBIL (mg/dL) 20.10 ± 11.24 0.07
HBV DNA level 17.17 ± 1.84 0.49whether HBV might influence the efficacy via some nega-
tive cytokine regulators. The JAK/STAT pathway is the
most important antiviral signaling transduction pathway
of IFN, and SOCS proteins induced by cytokines are the
key negative regulating proteins in the JAK/STAT path-
way. By inhibiting the activity of JAK and competitively
binding to the phosphorylated tyrosine residues in cyto-
kine receptors, SOCS proteins reduce the phosphorylation
of STATs. SOCS proteins also act as adaptor molecules to
guide the active cell signals to biodegradation pathway
[10]. Recently the SOCS-3 protein induced by HCV
core protein has been shown to be important for HCV
absconding from host INF [20,21]. However, there are
only a few studies on the correlation between HBV
and SOCS proteins, which focus on single HBV pro-
tein such as HBx protein. HBx has been shown to
affect the JAK/STAT pathway in the transfected hepa-
tocytes [22,23]. The subcellular mislocalization of the
mutant HBx has been found to up-regulate STAT3 ac-
tivation, resulting in STAT1 inhibition and SOCS-1
and SOCS-3 expression silencing. In the HBV-related
hepatocellular carcinoma, the dysregulation of STAT/
SOCS signaling is involved in the hepatocarcinogen-
esis [24-26].nd HBVDNA
OCS-1 SOCS-3














23.75 ± 5.60 25.50 ± 9.45 −0.48 0.64
Gender (Male/
Female)
7/1 6/10 – 0.03
Genotype
(A/B/C)
0/6/2 1/3/12 7.29 0.03
HBeAg (+/–) 8/0 16/0 – –
HBeAb (+/–) 0/8 0/16 – –
ALT (IU/L) 251.50 ± 108.03 205.19 ± 94.44 −1.03 0.31
AST (IU/L) 106.63 ± 36.92 107.19 ± 73.09 −0.02 0.98
ALB (g/L) 37.95 ± 1.48 36.49 ± 2.39 1.57 0.13
TBIL (mg/dL) 24.27 ± 13.63 25.62 ± 9.59 −0.28 0.78
CHE (U/L) 6218.50 ± 477.86 6677.25 ± 620.29 −1.83 0.08
CREA (mg/dL) 72.11 ± 62.02 67.49 ± 9.55 0.30 0.77
INR for PT 2.20 ± 0.41 2.02 ± 0.50 0.88 0.39
HBV DNA level 15.34 ± 1.29 18.09 ± 1.32 −4.85 0.001
SOCS-1 5.13 ± 1.89 15.38 ± 3.65 −7.40 0.001
SOCS-3 6.75 ± 1.58 20.63 ± 3.24 −11.37 0.001
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specimens from patients with CHB and was positively
correlated with the severity of inflammation. Same result
was also demonstrated in the cell culture. However, the
change of SOCS-1 level was not observed [27]. In our
animal studies, the change of the two SOCS proteins
was observed. The expression level of SOCS-1 andTable 5 Multivariate analysis of the factors affecting IFNα-2b
Prognostic factors Regression coefficent Standard error
Age 1.03 0.77
Gender 0.32 0.55
Genotype (A/B/C) 0.96 0.27
HBeAg (+/–) 0.86 0.31
HBeAb (+/–) −0.80 0.27
ALT (IU/L) −0.58 0.32
AST (IU/L) −1.93 0.34
ALB (g/L) 0.17 0.77
TBIL (mg/dL) 0.001 0.004
CHE (U/L) 2.18 1.23
CREA (mg/dL) −0.04 0.03




Cons −0.11 4.07SOCS-3 proteins varied in different groups. The higher
expression in Group B (pHBV4.1) as compared to Group
D (NS) suggested that HBV induced the expression of
SOCS-1 and SOCS-3 proteins. Poly IC is a well-known
inducer of the endogenous IFN. Therefore, the higher
expression of SOCS in Group A (pHBV4.1 + Poly IC)
than in Group C (Poly IC) suggested that HBV could
still induce SOCS expression with up-regulated en-
dogenous IFN. Moreover, the expression level in Group
C was higher than in Group D, suggesting that Poly IC
might induce the up-regulation of the endogenous IFN,
and then as a negative cytokine in IFN pathway, induce
the expression of SOCS-1 and SCOS-3 via some nega-
tive feedback pathway. As HBV and Poly IC were both
inducers, the expression level in Group A was supposed
to be higher. However, IFN is an inhibitor for HBV.
HBV inhibition-mediated decrease in SOCS-1 and SOCS-
3 expression might be stronger than IFN up-regulation
mediated increase in SOCS-1 and SOCS-3 expression,
leading to the higher expression level in Group B. The ex-
pression of SOCS-2 protein was not significantly different
among all groups, suggesting that HBV and Poly IC
couldn’t affect SOCS-2 expression.
In previous clinical studies on the IFN treatment in
CHB patients, the genotype and viral load of HBV were
considered as the key indicators for INF therapeutic effi-
cacy. Although many studies have focused on HBV, only a
few focus on the host factors that might affect the INF
therapeutic efficacy [4,28,29]. It has been reported previ-
ously that SOCS-1 and SOCS-3 proteins could down-
regulate the INF therapeutic efficacy as negative regulators
in the IFN signaling pathway in CHC patients, and thetherapeutic efficacy
Z value P value OR value 95% confidence interval
1.33 0.18 2.80 [-0.48~2.54]
0.58 0.03 1.37 [0.75~1.39]
3.51 0.04 2.62 [0.73~1.50]
2.80 0.75 2.37 [-0.26~1.47]
−2.92 0.63 0.45 [-1.34~1.27]
−1.82 0.07 0.56 [-1.21~0.05]
−5.65 0.96 0.14 [-2.60~1.26]
0.22 0.83 1.62 [-1.35~1.68]
1.40 0.16 1.00 [1.00~1.24]
1.78 0.08 8.91 [0.80-99.22]
−1.55 0.12 0.96 [0.91~1.01]
−1.94 0.05 0.99 [0.99~1.00]
2.03 0.04 1.00 [1.00~1.01]
−2.47 0.03 0.03 [0.01~0.47]
−2.02 0.04 0.08 [0.01~0.93]
−0.03 0.98 — —
Du et al. Virology Journal 2014, 11:51 Page 9 of 10
http://www.virologyj.com/content/11/1/51overexpression of SOCS-3 protein could be used for the
prognosis of CHC patients with INF treatment. Therefore,
it is possible that SOCS-1 and SOCS-3 proteins could
similarly affect the therapeutic efficacy in CHB patients by
negatively regulating IFN signaling transduction. Recently,
it has been shown that plasmacytoid dendritic cells
(pDCs) treated with HBsAg present a defect in INF-α se-
cretion due to HBsAg-mediated upregulation of SOCS-1
expression [30], which might partially explain the HBV
immune escape and persistent infection. In our clinical
observation, under a natural HBV infection status, same
results were obtained regarding the change of SOCS-1
and SOCS-3 as in the animal models. The higher expres-
sion of SOCS-1 and SOCS-3 in liver tissues of CHB patients
compared to the normal controls again demonstrated the
potential ability of HBV to induce SOCS-1 and SOCS-3. In
addition, we also found higher expression of the two SOCS
proteins in liver tissues in the responders as compared to
the non-responders, suggesting that the efficacy of INF
treatment might be impacted by the expression level of
SOCS-1 and SOCS-3 proteins before the treatment. Nega-
tive correlation between the expression of SOCS proteins
before treatment and the INF therapeutic efficacy was found
using both one-way ANOVA and multivariate analysis.
These results might explain why the patients with higher
expression of SOCS-1 and SOCS-3 proteins in liver before
treatment showed INF resistance, and the severity was
consistent with the expression level.
HBx and HBsAg are able to change the expression of
some SOCS proteins [24,30]. We showed that the most
important medical indicator, HBVDNA, did interact with
SOCS expression in CHB patients. In addition to the ex-
pression differences between the CHB patients and the
normal controls, the expression of SOCS proteins also
varied in patients with different viral load, which was
positively correlated with the expression level of SOCS-1
and SOCS-3 proteins. The higher the viral load, the
more expression of SOCS-1 and SOCS-3 in the liver tis-
sues, and the more effective in their ability to block IFN-
induced signaling pathway. Together with the results
from animal studies, our data explained why the viral
load is the most important indicator for IFN therapeutic
efficacy predication. HBV induced the expression of SOCS
proteins, which then inhibited IFN signaling transduction
pathway. As a result, IFN antiviral efficacy was decreased.
Thus, these results provided the theoretical foundation for
studying the relationship between SOCS proteins in
CHB patients before treatment and IFN therapeutic
efficacy, and explained why HBV appeared to play a
more important role than IFN in SOCS up-regulation.
However, since the transfection efficacy of hydro-
dynamic delivery in this mouse model in vivo was too
low, our findings need to be confirmed with further
investigations.In conclusion, HBV could induce SOCS-1 and SOCS-3
expression regardless of the level of the endogenous IFN.
The elevated IFN would directly up-regulate SOCS-1 and
SOCS-3 via some negative feedback pathway, and in-
directly down-regulate SOCS-1 and SOCS-3 by inhibiting
HBV. However, HBV played a more important role than
IFN in SOCS up-regulation, a possible reason why
patients with high HBV viral load would encounter poor
efficacy in IFN treatment. HBV induced SOCS proteins,
which could negatively regulate IFN signaling to decrease
IFN therapeutic efficacy, making the expression of SOCS-1
and SOCS-3 proteins in liver before treatment an import-
ant impact factor in IFN treatment for CHB. SOCS genes
can be the promising candidates in gene therapy and drug
development. For example, adenovirus vector expressing
the SOCS proteins can be used to treat rheumatic arthritis
[31]. Moreover, RNA interference and antisense nucleic
acid could also be used to down-regulate the SOCS expres-
sion, and some molecular compound could be used to
enhance or block its inhibition of the cytokine signaling
transduction [32]. New drugs for the JAK-STATs pathway
can be developed if detailed mechanism by which SOCS
proteins function under physiological and pathological
condition is understood. Anti-cytokine and anti-SOCS
proteins therapies might be the alternative opportunities
for patients with IFN resistance.
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